H3B-6527

DRUG2 trials

Sponsors

H3 Biomedicine Inc., Eisai Inc.

Conditions

Advanced Hepatocellular CarcinomaHealthy ParticipantsHepatic CancerHepatic CarcinomaHepatocellular CarcinomaLiver CancerLiver Neoplasms

Phase 1

Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma

CompletedNCT02834780

H3 Biomedicine Inc.Advanced Hepatocellular Carcinoma, Hepatic Cancer, Hepatic Carcinoma +3

Start: 2016-12-28End: 2022-02-23Updated: 2023-11-13

A Study to Evaluate the Food-Effect of H3B-6527

CompletedNCT03424577

Eisai Inc.Healthy Participants

Start: 2017-12-27End: 2018-01-27Updated: 2018-02-07

Related Papers

First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors.

2023-02-147 citations

Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC).

Journal of Clinical Oncology2021-05-2011 citations

A phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) patients (pts).

Journal of Clinical Oncology2019-05-2012 citations

Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers.

2018-10-272 citations